CF PharmTech, Inc. (02652) disclosed a repurchase of 27,500 ordinary H shares on 13 February 2026. The company indicates these repurchased shares, at an average price of HKD 34.9996 per share, have been transferred to treasury shares.

As of 13 February 2026, the number of issued shares (excluding treasury shares) stands at 301,941,586, while treasury shares total 282,000. The aggregate issued share capital remains at 302,223,586 shares. The aggregate price paid for the repurchase is HKD 962,490, with the highest repurchase price at HKD 35.2 and the lowest at HKD 34.7 per share.

The share repurchase follows a resolution dated 16 December 2025, which authorized up to 30,222,358 shares for repurchase. As of the announcement date, the total number of repurchased shares under this mandate is 282,000. A 30-day moratorium period on new share issuance or treasury share disposal is effective until 15 March 2026.